Merck (MRK) Offering Possible 9.41% Return Over the Next 29 Calendar Days

Merck’s most recent trend suggests a bullish bias. One trading opportunity on Merck is a Bull Put Spread using a strike $60.00 short put and a strike $55.00 long put offers a potential 9.41% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $60.00 by expiration. The full premium credit of $0.43 would be kept by the premium seller. The risk of $4.57 would be incurred if the stock dropped below the $55.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Merck is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Merck is bullish.

The RSI indicator is at 65.58 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Merck

Analysis: Motivating Factors Behind Pfizer’s Big Split
Mon, 16 Jul 2018 16:44:00 +0000
Pfizer, the worlds second largest pharmaceutical company, announced on Wednesday, July 11th, plans to split into three separate businesses in a major restructuring move. The Innovative Medicines division will bring in most of Pfizer’s revenue. In a press release, the company said that the growth potential for that business is strongest in part because of the aging population which will increase the demand for new medicines.

See what the IHS Markit Score report has to say about Merck & Co Inc.
Mon, 16 Jul 2018 12:01:34 +0000
Merck & Co Inc NYSE:MRK

[$$] Startup Producing Cell-Grown Meat Raises New Funding
Mon, 16 Jul 2018 11:00:03 +0000
and a top European meat processor are backing a startup producing beef from cattle cells, ramping up a race to transform the global meat industry with cell-culture technology. fuels a continuing effort to fulfill growing global demand for meat via a process that developers say requires a fraction of the resources used in traditional livestock and poultry production.

Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
Fri, 13 Jul 2018 12:50:12 +0000
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize
Fri, 13 Jul 2018 12:34:12 +0000
The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.

Be Sociable, Share!

Related Posts